Equity Profile

CRL

Charles River Laboratories International, Inc.

Health CareLife Sciences Tools & Services$8.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Charles River Laboratories Beats on EPS, Stock Down 0.03%

Metric	Actual	Expected	Surprise
EPS	$2.06	$1.94	+5.21%
Revenue	—	$977M	—

management commentary, guidance changes, and full analysis available with Pro.

Charles River Laboratories Beats on EPS, Stock Down 0.03%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.06	$1.94	+5.21%
Revenue	—	$977M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Charles River Laboratories reported better-than-expected earnings per share, which indicates strong performance in that area. However, the stock reacted slightly down by 0.03%, suggesting that investors may have been looking for more clarity on revenue or future guidance, which was not provided.

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, specifically in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

$1.94

Revenue

Total revenue gives insight into the company's sales performance and demand for its services, which is critical for growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, specifically in life sciences tools and services. The company plays a crucial role in supporting the pharmaceutical and biotechnology industries by providing essential services for drug development and testing, which are vital for bringing new therapies to market.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Charles River reported an EPS of $2.39, beating estimates by 2.49%. However, the stock experienced a slight decline the following day, indicating mixed market reactions.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CRL to report solid earnings this quarter, with a consensus EPS of $1.94. The market is watching closely for any signs of growth in revenue and profitability.

Bull Case

If CRL exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of declining revenue, it could raise concerns about its growth prospects, resulting in a negative market response.

Key Metrics to Watch

EPS

$1.94

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

Revenue

$977M

Total revenue gives insight into the company's sales performance and demand for its services, which is critical for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.94?

A beat on EPS could reinforce investor confidence in the company's profitability and growth trajectory.

What revenue guidance will management provide for the upcoming quarters?

Revenue guidance is crucial for assessing future growth potential and could significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRL's ability to capitalize on increasing demand for drug development services, given its strong track record.

Supporting Evidence

CRL has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the biotech sector show increased investment in R&D, which could benefit CRL.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRL can maintain its growth trajectory amid competitive pressures and economic conditions.

Bull Confirmed If

Earnings exceeding $1.94 with revenue growth above $977M would confirm a bullish outlook.

Bear Confirmed If

Failing to meet the $1.94 EPS and showing stagnant or declining revenue would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±11.28%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.3% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

52.4%

Calls (2K)P/C Ratio: 0.11Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests the stock could rise by around 1.0%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response, as investors assess management's commentary for future guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 0.0% when missing expectations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new service offerings or partnerships that could drive revenue growth.
2Management's commentary on market demand trends in the biotech sector.
3Insights into cost management strategies and their impact on margins.
4Any changes in guidance for the upcoming quarters, particularly regarding revenue.
5Discussion on competitive pressures and how CRL plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

AXSOME THERAPEUTICS

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, specifically in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

$1.94

Revenue

Total revenue gives insight into the company's sales performance and demand for its services, which is critical for growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Charles River reported an EPS of $2.39, beating estimates by 2.49%. However, the stock experienced a slight decline the following day, indicating mixed market reactions.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CRL to report solid earnings this quarter, with a consensus EPS of $1.94. The market is watching closely for any signs of growth in revenue and profitability.

Bull Case

If CRL exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of declining revenue, it could raise concerns about its growth prospects, resulting in a negative market response.

Key Metrics to Watch

EPS

$1.94

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profit.

Revenue

$977M

Total revenue gives insight into the company's sales performance and demand for its services, which is critical for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.94?

A beat on EPS could reinforce investor confidence in the company's profitability and growth trajectory.

What revenue guidance will management provide for the upcoming quarters?

Revenue guidance is crucial for assessing future growth potential and could significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRL's ability to capitalize on increasing demand for drug development services, given its strong track record.

Supporting Evidence

CRL has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the biotech sector show increased investment in R&D, which could benefit CRL.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRL can maintain its growth trajectory amid competitive pressures and economic conditions.

Bull Confirmed If

Earnings exceeding $1.94 with revenue growth above $977M would confirm a bullish outlook.

Bear Confirmed If

Failing to meet the $1.94 EPS and showing stagnant or declining revenue would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±11.28%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.3% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

52.4%

Calls (2K)P/C Ratio: 0.11Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests the stock could rise by around 1.0%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response, as investors assess management's commentary for future guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 0.0% when missing expectations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new service offerings or partnerships that could drive revenue growth.
2Management's commentary on market demand trends in the biotech sector.
3Insights into cost management strategies and their impact on margins.
4Any changes in guidance for the upcoming quarters, particularly regarding revenue.
5Discussion on competitive pressures and how CRL plans to address them.